Lawsuits Accuse GLP-1 Weight-Loss Drugs of Rare Vision Loss

Dozens of U.S. plaintiffs allege GLP-1 drugs such as Ozempic, Wegovy and Mounjaro cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare, potentially permanent loss of vision. The suits claim warnings were inadequate, with cases arising within 6–18 months of starting treatment. Novo Nordisk and Eli Lilly are contesting the claims, while regulators report mixed evidence and emphasize the overall low risk, even as the GLP-1 market faces scrutiny and potential impact from litigation.